Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
05/05/2026 13:38
May 5 (Reuters) - Oragenics Inc OGEN.A: ORAGENICS ACTIVATES SECOND SITE IN PHASE IIA CLINICAL TRIAL OF ONP-002 FOR CONCUSSION AND MILD TRAUMATIC BRAIN INJURY. ORAGENICS INC: PHASE IIA CLINICAL DATA READOUT IS PROJECTED BEFORE YEAR-END 2026 ORAGENICS:PHASE IIA CLINICAL DATA READOUT TO SUPPORT PLANNED IND APPLICATION SUBMISSION TO FDA,TARGETING DEC 31 FOR PHASE IIB CLINICAL TRIAL IN U.S. Source text: ID:nGNXt3plT Further company coverage: OGEN.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing